Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Frost & Sullivan Acknowledges LEUKOCARE Early Mover Initiative in the Biotechnology Industry its Path Breaking Technology and Sound Management Backing - The company provides technologies for next generation’s medicinal products - LEUKOCARE.com
Frost & Sullivan Acknowledges LEUKOCARE Early Mover Initiative in the Biotechnology Industry its Path Breaking Technology and Sound Management Backing

 

PRZOOM - /newswire/ - London, United Kingdom, 2012/04/26 - The company provides technologies for next generation’s medicinal products - LEUKOCARE.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the biotechnology industry, Frost & Sullivan recognizes LEUKOCARE with the 2011 Europe Frost & Sullivan Award for Early Stage Investment Opportunity. LEUKOCARE is a leading provider of technologies for biological functionalization of medical devices, as well as the stabilization and protection of proteins and biological molecules in biopharmaceutical formulations in order to ensure safety, to extend shelf-life and to enable terminal sterilization. The enabling technology platform branded as Stabilizing and Protecting Solution (SPS®) is offered to industrial partners in license-based development collaborations. LEUKOCARE’s IP is protected by patents in various patent families. The company has implemented a quality management system for its services in design, development, manufacturing and distribution of technologies and products.

LEUKOCARE’s SPS technology increases the value of biopharmaceutical products and diagnostics: Numerous proteins and other biological molecules loose their pharmacological activity when exposed to physical or chemical stress, LEUKOCARE’s SPS excipient platform increases shelf-life by protecting the structure of these fragile molecules. This way, cold chain distribution of vaccines can be avoided and sterilization by irradiation is tolerated without loss of function.

LEUKOCARE positions itself as one of the few companies that combines biologics with medical devices. It offers R&D services during early planning and design (identifying pathways and effector molecules), prototyping and product development.

“The company has successfully designed, developed and clinically tested a biologic-combination device with therapeutic impact on the immune system,” said Frost & Sullivan Research Analyst Janani Sankaran. “LEUKOCARE currently partners with a significant number of biopharmaceutical companies to implement it’s technologies in next generation’s products.”

LEUKOCARE has had a remarkable funding history with the German state-owned bank KfW, which invested through its equity-program ‘ERP-Startfonds’ in 2006. More recently, in November 2010, it received another round of funding worth $2.0 million. The company’s experienced management has been one of the chief reasons for the company’s ability to attract investments.

“LEUKOCARE’s business model is hybrid; it is a combination of fee for service and licensing where royalties are paid,” noted Sankaran.” Although LEUKOCARE’s value proposition is comparable, its IP is distinct because of clearly distinguishable molecules.”

The company charges a licensing fee, which is approximately 1-5 per cent of its net sales. It saves 50 per cent of the logistics costs, which is split equally between the pharmaceutical company and LEUKOCARE. Its SPS technology can enable a 20 per cent savings on production costs for biopharmaceuticals and up to 75 per cent on production costs of biologic-device combination products.

“LEUKOCARE creates awareness of its technology-based platform by presenting at scientific conferences, identifying key opinion leaders and convincing them about the cost savings and safety benefits of its products,” remarked Sankaran. “It also partners with early-stage companies to reduce regulatory costs and with late stage companies to extend its solutions’ patent life by introducing novel drugs/molecules.”

Currently, almost 100 per cent of LEUKOCARE’s sales is generated by North America and the European Union. In five years, with improved awareness, LEUKOCARE aims to account for at least 5 per cent of the total market.

Each year, Frost & Sullivan presents this award to the company that demonstrates strength of intellectual property, expertise in team management and innovation in product differentiation strategies.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About LEUKOCARE
LEUKOCARE (LEUKOCARE.com) is a leading provider of technologies for biological functionalization of medical devices, as well as the stabilization and protection of proteins and biological molecules in biopharmaceutical formulations in order to ensure safety, to extend shelf-life and to enable terminal sterilization.

As a product-focused biotechnology company, LEUKOCARE uses its proprietary Stabilizing and Protecting Solutions (SPS) to leverage its comprehensive expertise in industrial co-development partnerships. The company offers its know-how in formulation of biologics, biofunctional coatings of combination devices and product development.

LEUKOCARE was founded in 2003 and is headquartered in Martinsried near Munich, Germany.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Acknowledges LEUKOCARE Early Mover Initiative in the Biotechnology Industry its Path Breaking Technology and Sound Management Backing

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan | LEUKOCARE
Contact: Catherine Brassell 
+44(0)20 7915 7867 catherine.brassell[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Triggr & Bloom

Visit  BizJobs.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today